Clinical Research Directory
Browse clinical research sites, groups, and studies.
SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC
Sponsor: Sun Yat-sen University
Summary
This is a phase II, open-label, single-arm study evaluating the efficacy and safety of SHR-A1811 (a HER2-targeted ADC) combined with AK112 (a PD-1/VEGF bispecific antibody) in patients with HER2-amplified or overexpressed locally advanced or metastatic NSCLC.
Official title: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of SHR-A1811 Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With HER2 Abnormalities
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-04-30
Completion Date
2028-12-31
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
SHR-A1811 plus AK112
Patients will receive the combination of SHR-A1811 and AK112 until disease progression or until other predefined discontinuation criteria are met, whichever occurs first.